Paper Details

  1. Home
  2. Paper Details

Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Author: AdkinsDouglas R, AhnMyung-Ju, AlonsoGuzman, BarataTeresa, BordognaWalter, BroseMarcia, CassierPhilippe A, Chul ChoByoung, CuriglianoGiuseppe, GainorJustin F, GodbertYann, HadouxJulien, HeinzmannSebastian, HuMimi I, LinChia-Chi, MansfieldAaron S, ScaloriAstrid, SchulerMartin, SubbiahVivek, TaylorMatthew H, TraskPeter, WirthLori, ZalutskayaAlena, ZhuViola W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study presents an updated analysis of the ARROW study, which evaluated the efficacy and safety of pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. The analysis confirms the clinical activity and manageable safety profile of pralsetinib in this patient population.
Paper Details　
Original Abstract of the Article :
RET alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. We present an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/thy.2023.0363

データ提供：米国国立医学図書館（NLM）

Pralsetinib: A New Oasis in the Desert of RET-altered Thyroid Cancer

RET-altered thyroid cancer presents significant challenges in treatment. This study provides an updated analysis of pralsetinib, a selective RET inhibitor, showcasing its efficacy and safety in patients with advanced/metastatic RET-altered thyroid cancer. It’s like discovering a new oasis in the arid desert of RET-altered thyroid cancer, offering a potentially life-changing treatment option.

Pralsetinib: A Beacon of Hope

The study highlights the clinical activity and manageable safety profile of pralsetinib, offering a promising therapeutic approach for patients with advanced/metastatic RET-altered thyroid cancer. It’s like finding a reliable source of water in a harsh desert environment, providing a lifeline of hope for those battling this challenging disease.

Navigating the Desert of Thyroid Cancer

This updated analysis of pralsetinib provides valuable insights into its potential as a targeted therapy for RET-altered thyroid cancer. It underscores the importance of ongoing research and development in this crucial area of cancer care. Think of it as a compass guiding us through the desert of thyroid cancer, leading to new treatments and better outcomes.

Dr. Camel's Conclusion

This updated analysis of pralsetinib offers a beacon of hope for patients with advanced/metastatic RET-altered thyroid cancer. It highlights the potential of targeted therapies in improving treatment outcomes. It’s a reminder that even in the most challenging deserts, there are pathways to innovation and hope.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-27
Further Info :

Pubmed ID

38009200

DOI: Digital Object Identifier

10.1089/thy.2023.0363

Related Literature

Article Analysis
・Effects of pralsetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.